Take the tour Book a demo

US FDA cGMP21 CFR 210 & 211

FDA cGMP software mapped to 21 CFR 210 and 211.

Current Good Manufacturing Practice under 21 CFR 210 and 211 decides what a US-market manufacturer must control and record. Swat iQua Suite, as FDA cGMP software, puts those controls in the workflow — from component testing to batch records, laboratory controls, record review and distribution.

  • Identity testing on every received lot
  • Electronic batch records with yield and limits
  • Laboratory controls with second-person review
  • Release blocked until investigations close
Book a free demo 21 CFR Part 11
Electronic batch record step with process parameters checked against limits

The regulation

What FDA cGMP requires — 21 CFR 210/211 compliance in practice.

Parts 210 and 211 set the minimum current good manufacturing practice for finished pharmaceuticals in the United States. Part 210 covers status and definitions; Part 211 sets out the requirements, subpart by subpart.

Part 211 is organised around the life of a product in the plant. It covers organisation and personnel, buildings and facilities, equipment, the control of components and drug product containers and closures, production and process controls, packaging and labelling, holding and distribution, laboratory controls, records and reports, and returned and salvaged drug products. Each subpart asks the same underlying question: can you show — from records made at the time — that the product was made, tested and released as intended?

The sections that shape your records

  • 211.22 — the quality control unit has the responsibility and authority to approve or reject components, in-process materials, finished products and the procedures that affect them.
  • 211.25 — personnel must have the education, training and experience for their duties, including training in cGMP and in the procedures they follow.
  • 211.68 — automatic, mechanical and electronic equipment, including computers, must be controlled so that only authorised people can change master records and data, with input and output checked.
  • 211.84 — components are held in quarantine until sampled, tested or examined, and released by the quality unit; at least one identity test is performed on each lot.
  • 211.100 and 211.186 — written, approved production and process control procedures and master production records; deviations must be recorded and justified.
  • 211.103 and 211.110 — actual yields are calculated at appropriate phases, and in-process controls monitor the output of steps that may cause variability.
  • 211.125 — labelling is issued under control and reconciled; discrepancies outside limits are investigated.
  • 211.160, 211.165, 211.166 and 211.194 — scientifically sound specifications and test procedures, testing for release, a written stability programme and complete laboratory records.
  • 211.180(e), 211.188 and 211.192 — an annual review of product quality, batch production and control records for every batch, and a quality unit review of those records with thorough investigation of any unexplained discrepancy before release.

Where FDA 483 observations cluster

Public FDA Form 483 observations and warning letters return again and again to the same themes: investigations of discrepancies and out-of-specification results that are incomplete or late (211.192), quality unit responsibilities not exercised (211.22), procedures not followed (211.100), laboratory controls that are not scientifically sound (211.160) and computerised system controls that let data be changed or deleted without a trace (211.68). These are exactly the places where a paper or spreadsheet process depends on discipline, and where a system can enforce the rule instead.

Requirement → module

21 CFR 211 topics, mapped to Swat iQua Suite.

Each capability below is enforced in the platform — the record cannot move on until the rule is met.

  • 211.84 — Components

    Material enters only through a posted goods receipt, as a quarantine lot. Identity is always tested; reduced testing depends on the manufacturer site’s qualification and conforming history.

    • QA release needs a conforming CoA, identity pass, approved tests and no OOS
    • Only released stock can be dispensed
    GMP warehouse

  • 211.186 / 211.188 — Batch records

    Versioned master formulas and process instructions; each batch snapshots the approved versions and runs step by step, with an Executed Batch Record PDF including signers, deviations and audit trail.

    eBMR software

  • 211.103 / 211.110 — Yield & in-process

    Critical parameter readings are checked against limits; an out-of-limit reading raises a deviation and corrections never overwrite the original. Yield is captured and classified at close.

  • 211.25 — Training

    SOP-based training with server-graded exams. A batch step or dispensing session cannot start unless the operator is trained on the linked SOPs.

    Training management

  • 211.125 — Labelling control

    Printed components (labels, cartons, leaflets) are reconciled — issued, used, returned and destroyed — and packaging cannot complete until the count balances or QA approves the discrepancy.

    Packaging

  • 211.160 / 211.165 / 211.194 — Laboratory

    Approved specifications frozen per sample, results locked on submission, reviewer ≠ analyst, raw data stored with a SHA-256 hash, and tests only on calibrated instruments.

    Pharma LIMS

  • 211.166 — Stability

    Approved stability protocols with server-computed pull schedules, late pulls flagged, and ICH Q1E regression trend and shelf-life reporting.

    Stability studies

  • 211.22 / 211.192 — Review & release

    The release checklist cannot be attested while linked deviations, OOS or CAPAs still block. The QA releaser cannot be the batch operator, and the decision is e-signed.

    Batch release

  • 211.150 — Distribution

    Shipments accept only QA-released lots, and any lot can be traced forward to customers and back to raw-material lots to support a recall.

    Traceability & recall

Investigations

A discrepancy cannot slip past release.

Section 211.192 expects any unexplained discrepancy to be thoroughly investigated before release. In Swat iQua Suite the records are linked, so the release dossier knows.

  1. eBMRStep 5

    Out-of-limit reading

    Recorded where it happened; a deviation is raised from the step.

    Deviation open

  2. QMSDEV/2026/0016

    Investigation & CAPA

    Reviewed, approved and decided by different people, with a linked CAPA.

    In progress

  3. ReleaseChecklist

    “Deviations closed”

    Cannot be attested while the linked deviation or CAPA still blocks.

    Blocked

  4. QABatch 26/0002

    Release decision

    Once closed, QA releases with an e-signature — never the batch operator.

    Released

Deviation, CAPA, retest and release — linked records in one audit trail.

Shared responsibility

What stays with your quality unit.

Part 211 places responsibility on the manufacturer and its quality unit. Software enforces and records; people decide.

Your organisation writes and approves the procedures the system enforces, qualifies facilities and equipment, validates its processes and its installation of Swat iQua Suite, and trains its people. Your quality unit still makes every disposition decision — the platform makes sure it is taken by an authorised person, on complete evidence, and recorded.

  • Procedures — your SOPs, specifications, master formulas and sampling plans, approved through the system’s controlled workflows.
  • Facilities, equipment and cleaning — qualification and cleaning validation remain part of your validation programme.
  • Computerised system validation — validating your installation for its intended use under 211.68 and Part 11. We support it with requirements traceability and evidence of the controls.
  • Product quality review — Swat iQua Suite assembles a frozen snapshot of batch, deviation, CAPA, OOS, change control and EM figures for the period; the evaluation and conclusions are your quality unit’s.
  • Complaints and returned goods — handled under your procedures.

Swat iQua Suite is designed to support compliance with US cGMP and 21 CFR Part 11 — the evidence your quality unit needs, recorded as the work happens.

Keep exploring

Related regulations

FAQ

Frequently asked questions

Can’t find your answer? Talk to our team — we reply within one business day.

Is Swat iQua Suite FDA approved?

The FDA does not approve or certify manufacturing software. It inspects manufacturers. Swat iQua Suite is designed to support compliance with 21 CFR 210/211 and 21 CFR Part 11, and evidence packages for FDA inspections can be assembled from the same records.

How does it help with 211.84 component testing?

Every received lot lands in quarantine through a posted goods receipt. Identity is always tested; reduced testing is decided at receipt from the manufacturer site’s qualification and conforming lot history, and resets on OOS or deviation. QA release is evidence-gated and e-signed, and only released stock can be dispensed.

Does it meet 211.188 batch record content?

The electronic batch record captures each step, parameter, correction, signer, deviation and attachment, with yield classified at close, and prints as an Executed Batch Record with the full audit trail. Whether your records meet 211.188 is confirmed by your own review against your master production records.

Can it reduce repeat 483 observations?

It removes the gaps where 483 observations often start: investigations that stay open at release, procedures that are skipped, results reviewed by the person who produced them, and data changed without a trace. Inspection outcomes still depend on your whole quality system.

Does it print labels or serialise packs?

No. Packaging in Swat iQua Suite reconciles printed components — issued, used, returned and destroyed — before completion. Label printing on the line and serialisation are handled by your existing equipment.

Does it support the annual product review?

Product Quality Review collects batch, deviation, CAPA, OOS, change control and EM figures for the review period into a snapshot that cannot be changed, then goes through e-signed approval. Your quality unit writes the evaluation.

Ready to see Swat iQua Suite in action?

Book a free, personalised demo and see how Swat iQua Suite takes your plants, labs and quality teams from paper to inspection-ready.

Download the brochure →